In the latest trading session, Novo Nordisk (NVO) closed at $38.52, marking a -1.61% move from the previous day. This move lagged the S&P 500’s daily loss of 0.41%. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq depreciated by 0.89%.<\/p>\n
Heading into today, shares of the drugmaker had gained 7.76% over the past month, outpacing the Medical sector’s gain of 0.47% and lagging the S&P 500’s gain of 9.71%.<\/p>\n
The investment community will be paying close attention to the earnings performance of Novo Nordisk in its upcoming release. On that day, Novo Nordisk is projected to report earnings of $0.87 per share, which would represent a year-over-year decline of 5.43%. Alongside, our most recent consensus estimate is anticipating revenue of $11.13 billion, indicating a 1.08% upward movement from the same quarter last year.<\/p>\n
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.34 per share and a revenue of $45.22 billion, signifying shifts of -15.66% and -3.32%, respectively, from the last year.<\/p>\n
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Novo Nordisk. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts’ confidence in the business performance and profit potential.<\/p>\n
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we’ve formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.<\/p>\n
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.51% lower. Right now, Novo Nordisk possesses a Zacks Rank of #3 (Hold).<\/p>\n
From a valuation perspective, Novo Nordisk is currently exchanging hands at a Forward P\/E ratio of 11.74. For comparison, its industry has an average Forward P\/E of 14.03, which means Novo Nordisk is trading at a discount to the group.<\/p>\n
It’s also important to note that NVO currently trades at a PEG ratio of 9.32. Comparable to the widely accepted P\/E ratio, the PEG ratio also accounts for the company’s projected earnings growth. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.24 as of yesterday’s close.<\/p>\n
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 168, putting it in the bottom 32% of all 250+ industries.<\/p>\n","protected":false},"excerpt":{"rendered":"In the latest trading session, Novo Nordisk (NVO) closed at $38.52, marking a -1.61% move from the previous…\n","protected":false},"author":2,"featured_media":67301,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[4862,272,13101,4861,1278],"class_list":["post-67300","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-medical-sector","tag-novo-nordisk","tag-pharmaceuticals-industry","tag-sp-500","tag-zacks-rank"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116456765969146565","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/67300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=67300"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/67300\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/67301"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=67300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=67300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=67300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}